Zheng S - Search Results

1

APOBEC3G acts as a therapeutic target in mesenchymal gliomas by sensitizing cells to radiation-induced cell death.

Wang Y, Wu S, Zheng S, Wang S, Wali A, Ezhilarasan R, Sulman EP, Koul D, Alfred Yung WK. Wang Y, et al. Among authors: zheng s. Oncotarget. 2017 Apr 21;8(33):54285-54296. doi: 10.18632/oncotarget.17348. eCollection 2017 Aug 15. Oncotarget. 2017. PMID: 28903341 Free PMC article.

2

A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival.

Zheng S, Fu J, Vegesna R, Mao Y, Heathcock LE, Torres-Garcia W, Ezhilarasan R, Wang S, McKenna A, Chin L, Brennan CW, Yung WK, Weinstein JN, Aldape KD, Sulman EP, Chen K, Koul D, Verhaak RG. Zheng S, et al. Genes Dev. 2013 Jul 1;27(13):1462-72. doi: 10.1101/gad.213686.113. Epub 2013 Jun 24. Genes Dev. 2013. PMID: 23796897 Free PMC article.

3

A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells.

Saito N, Fu J, Zheng S, Yao J, Wang S, Liu DD, Yuan Y, Sulman EP, Lang FF, Colman H, Verhaak RG, Yung WK, Koul D. Saito N, et al. Among authors: zheng s. Stem Cells. 2014 Jan;32(1):301-12. doi: 10.1002/stem.1528. Stem Cells. 2014. PMID: 24038660 Free PMC article.

4

MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.

Wu S, Wang S, Zheng S, Verhaak R, Koul D, Yung WK. Wu S, et al. Among authors: zheng s. Mol Cancer Ther. 2016 Jul;15(7):1656-68. doi: 10.1158/1535-7163.MCT-15-0857. Epub 2016 Apr 22. Mol Cancer Ther. 2016. PMID: 27196759 Free PMC article.

5

Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.

Koul D, Wang S, Wu S, Saito N, Zheng S, Gao F, Kaul I, Setoguchi M, Nakayama K, Koyama K, Shiose Y, Sulman EP, Hirota Y, Yung WKA. Koul D, et al. Among authors: zheng s. Oncotarget. 2017 Mar 28;8(13):21741-21753. doi: 10.18632/oncotarget.15566. Oncotarget. 2017. PMID: 28423515 Free PMC article.

6

ARID1B alterations identify aggressive tumors in neuroblastoma.

Lee SH, Kim JS, Zheng S, Huse JT, Bae JS, Lee JW, Yoo KH, Koo HH, Kyung S, Park WY, Sung KW. Lee SH, et al. Among authors: zheng s. Oncotarget. 2017 Jul 11;8(28):45943-45950. doi: 10.18632/oncotarget.17500. Oncotarget. 2017. PMID: 28521285 Free PMC article.

7

Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.

Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel F, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Sauvé CG, Olar A, Lan ZD, Finocchiaro G, Phillips JJ, Berger MS, Gabrusiewicz KR, Wang G, Eskilsson E, Hu J, Mikkelsen T, DePinho RA, Muller F, Heimberger AB, Sulman EP, Nam DH, Verhaak RGW. Wang Q, et al. Among authors: zheng s. Cancer Cell. 2017 Jul 10;32(1):42-56.e6. doi: 10.1016/j.ccell.2017.06.003. Cancer Cell. 2017. PMID: 28697342 Free PMC article.

8

Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma.

Wu S, Wang S, Gao F, Li L, Zheng S, Yung WKA, Koul D. Wu S, et al. Among authors: zheng s. Neuro Oncol. 2018 Jan 10;20(1):78-91. doi: 10.1093/neuonc/nox128. Neuro Oncol. 2018. PMID: 29016926 Free PMC article.

9

Tie2-FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma.

Li X, Martinez-Ledesma E, Zhang C, Gao F, Zheng S, Ding J, Wu S, Nguyen N, Clifford SC, Wen PY, Ligon KL, Yung WKA, Koul D. Li X, et al. Among authors: zheng s. Cancer Res. 2019 Oct 1;79(19):5088-5101. doi: 10.1158/0008-5472.CAN-19-0325. Epub 2019 Aug 15. Cancer Res. 2019. PMID: 31416846

10

EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma.

Wu S, Gao F, Zheng S, Zhang C, Martinez-Ledesma E, Ezhilarasan R, Ding J, Li X, Feng N, Multani A, Sulman EP, Verhaak RG, de Groot JF, Heffernan TP, Yung WKA, Koul D. Wu S, et al. Among authors: zheng s. Clin Cancer Res. 2020 Mar 15;26(6):1395-1407. doi: 10.1158/1078-0432.CCR-19-2549. Epub 2019 Dec 18. Clin Cancer Res. 2020. PMID: 31852834

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

12,835 results

Search Page